Kingswood Wealth Advisors LLC Has $2.38 Million Position in Humana Inc. (NYSE:HUM)

Kingswood Wealth Advisors LLC boosted its holdings in Humana Inc. (NYSE:HUM) by 23.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,379 shares of the insurance provider’s stock after acquiring an additional 1,751 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Humana were worth $2,380,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV grew its position in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Atwood & Palmer Inc. purchased a new position in shares of Humana during the third quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in Humana in the third quarter worth about $31,000. Your Advocates Ltd. LLP grew its holdings in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the last quarter. Finally, LRI Investments LLC lifted its position in Humana by 1,021.4% during the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after purchasing an additional 143 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Up 0.2 %

Shares of HUM stock opened at $294.47 on Monday. The stock’s 50 day simple moving average is $274.39 and its 200 day simple moving average is $304.79. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a market capitalization of $35.46 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, research analysts predict that Humana Inc. will post 16.11 EPS for the current year.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Oppenheimer decreased their price objective on shares of Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, October 3rd. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. UBS Group reduced their price objective on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, October 4th. KeyCorp began coverage on shares of Humana in a research note on Friday, October 11th. They set a “sector weight” rating for the company. Finally, Piper Sandler upped their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Humana has an average rating of “Hold” and a consensus target price of $297.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.